company background image
CUV

Clinuvel Pharmaceuticals ASX:CUV Stock Report

Last Price

AU$20.00

Market Cap

AU$988.2m

7D

8.2%

1Y

-30.4%

Updated

04 Dec, 2022

Data

Company Financials +
CUV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance2/6
Financial Health6/6
Dividends0/6

CUV Stock Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Clinuvel Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clinuvel Pharmaceuticals
Historical stock prices
Current Share PriceAU$20.00
52 Week HighAU$30.36
52 Week LowAU$13.16
Beta0.88
1 Month Change2.56%
3 Month Change1.68%
1 Year Change-30.44%
3 Year Change-24.13%
5 Year Change150.00%
Change since IPO1,900.00%

Recent News & Updates

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Recent updates

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Shareholder Returns

CUVAU BiotechsAU Market
7D8.2%0.9%0.6%
1Y-30.4%-1.6%-1.8%

Return vs Industry: CUV underperformed the Australian Biotechs industry which returned -1.6% over the past year.

Return vs Market: CUV underperformed the Australian Market which returned -1.8% over the past year.

Price Volatility

Is CUV's price volatile compared to industry and market?
CUV volatility
CUV Average Weekly Movement7.7%
Biotechs Industry Average Movement8.8%
Market Average Movement9.0%
10% most volatile stocks in AU Market15.9%
10% least volatile stocks in AU Market4.1%

Stable Share Price: CUV is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CUV's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aPhilippe Wolgenhttps://www.clinuvel.com

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

Clinuvel Pharmaceuticals Limited Fundamentals Summary

How do Clinuvel Pharmaceuticals's earnings and revenue compare to its market cap?
CUV fundamental statistics
Market CapAU$988.21m
Earnings (TTM)AU$20.88m
Revenue (TTM)AU$66.17m

47.3x

P/E Ratio

14.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CUV income statement (TTM)
RevenueAU$66.17m
Cost of RevenueAU$9.25m
Gross ProfitAU$56.92m
Other ExpensesAU$36.04m
EarningsAU$20.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.42
Gross Margin86.02%
Net Profit Margin31.55%
Debt/Equity Ratio0%

How did CUV perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

9%

Payout Ratio